2018 Acute Coronary Syndrome Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Acute Coronary Syndrome Market

June 2018 | 70 pages | ID: 2E89364FB3DEN
VPAResearch

Abstracts

Worldwide, an estimated 2 to 3 million people are hospitalized due to ACS annually. The acute coronary syndrome is a common complication of coronary heart disease. ACS refers to a broad range of diseases including Unstable angina, Non-ST segment elevation MI, ST-segment elevation MI. A sudden decrease in blood flow into the heart is observed, eventually resulting in thrombotic occlusion of a coronary artery. A sustained block of blood flow to the heart causes the death of the muscle tissue.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Acute Coronary Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Acute Coronary Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Acute Coronary Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 ACUTE CORONARY SYNDROME PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Acute Coronary Syndrome Pipeline Snapshot
2.3 Acute Coronary Syndrome Pipeline by Phase
2.4 Acute Coronary Syndrome Pipeline by Company
2.5 Acute Coronary Syndrome Pipeline by Mechanism of Action

3 ACUTE CORONARY SYNDROME- COMPANY WISE PIPELINE ANALYSIS

Actelion Pharmaceuticals Ltd.
advanceCor GmbH
Allergan plc
Ascendia Pharmaceuticals LLC
Bayer AG
Cardiome Pharma Corp.
Cerenis Therapeutics Holding SA
CSL Limited
DalCor Pharmaceuticals Canada Inc.
PT. Dexa Medica
HitGen LTD
LipimetiX Development Inc
MedImmune LLC
Pfizer Inc.
Resverlogix Corporation
Verseon Corporation

4 ACUTE CORONARY SYNDROME R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ACUTE CORONARY SYNDROME PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Acute Coronary Syndrome Pipeline by Phase, H2- 2018
Figure 2: Acute Coronary Syndrome Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Acute Coronary Syndrome Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Acute Coronary Syndrome Pipeline by Phase, H2- 2018
Acute Coronary Syndrome Pipeline by Companies, H2- 2018
Acute Coronary Syndrome Pipeline by Mechanism of Action, H2- 2018
Table 1: Actelion Pharmaceuticals Ltd. Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 2: advanceCor GmbH Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 3: Allergan plc Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 4: Ascendia Pharmaceuticals LLC Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 5: Bayer AG Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 6: Cardiome Pharma Corp. Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 7: Cerenis Therapeutics Holding SA Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 8: CSL Limited Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 9: DalCor Pharmaceuticals Canada Inc. Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 10: PT. Dexa Medica Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 11: HitGen LTD Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 12: LipimetiX Development Inc Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 13: MedImmune LLC Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 14: Pfizer Inc. Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 15: Resverlogix Corporation Acute Coronary Syndrome Pipeline Drugs, H2- 2018
Table 16: Verseon Corporation Acute Coronary Syndrome Pipeline Drugs, H2- 2018